AMY-101 acetate is a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM). AMY-101 (Cp40) can improve the periodontal condition of NHPs with natural chronic periodontitis.
|Solubility (25°C)||DMSO 90 mg/mL|
|Storage||-20°C, protect from light, dry, sealed|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Related Complement System Products|
BR103 is a C3aR-specific small molecule ligand.
3-Phenoxybenzaldehyde has weak complement classical pathway inhibition and hemolytic activity.
NH2-C6-ARC186 is a modified ARC186 with NH2-C6 that can be coupled to other peptides or molecules.
Zilucoplan TFA (RA101495) is a 15 amino acid macrocyclic peptide and potent complement component 5 (C5) inhibitor that specifically targets C5, a component of the terminal complement activation pathway, thereby preventing the cleavage of C5 by C5 converting enzyme to complement components C5a and C5b, and thus preventing the downstream assembly and activity of the membrane attack complex (MAC). Can be used in studies related to immune-mediated necrotizing myopathy (IMNM) and generalized myasthenia gravis (gMG).
Complement C1s-IN-1 is a potent, selective, orally active and cross the blood-brain barrier C1s inhibitor with an IC50 value of 36 nM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.